Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00363298 · ClinicalTrials.gov registry record · NA
Dextro-Amphetamine Versus Caffeine in Treatment-resistant OCD
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT00363298: Completed NA study, sponsored by Stanford University.
NCT00363298 is a NA study that has completed, run by Stanford University. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00363298, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
The study hypothesis is that dextro-amphetamine (d-amphetamine) will be safe and effective when used to augment treatment for Obsessive-Compulsive Disorder (OCD), and that tolerance (loss of therapeutic effect) to the medication will not develop over a period of several weeks.
Interventions
- DRUG dextro-amphetamine
- DRUG Sham Comparison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2006-08 |
| Est. Completion | 2008-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00363298
The ClinicalTrials.gov registry entry for NCT00363298 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which dextro-amphetamine is the first listed.
NCT00363298 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00363298 about?
NCT00363298 is a clinical study titled "Dextro-Amphetamine Versus Caffeine in Treatment-resistant OCD". The study hypothesis is that dextro-amphetamine (d-amphetamine) will be safe and effective when used to augment treatment for Obsessive-Compulsive Disorder (OCD), and that tolerance (loss of therapeutic effect) to the medication will not develop over a period of several weeks.
What is the current status of trial NCT00363298?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2006-08. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00363298?
The interventions under investigation include: dextro-amphetamine (DRUG), Sham Comparison (DRUG).
Who is sponsoring clinical trial NCT00363298?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.